Source:http://linkedlifedata.com/resource/pubmed/id/12581569
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2003-2-12
|
| pubmed:abstractText |
Alterations of the p53 gene may lead to the production of detectable autoantibodies (p53-Abs) in cancer patients. In order to evaluate the association of p53-Abs with pleuropulmonary diseases, four groups of subjects were analyzed by ELISA for serum p53-Abs, in the framework of a molecular epidemiologic study. Two of 30 pleural malignant mesothelioma patients (MM; 6.7%) and 8/48 lung cancer patients (LC; 16.7%) were seropositive, while all 51 healthy controls (HC) were negative. Two of 55 (3.6%) at-risk controls (RC) with non-malignant respiratory diseases were positive and were not subsequently diagnosed any cancer. The difference was statistically significant between LC and RC or HC (P = 0.01), but not between MM and any other group. No correlation was found with age, sex, cancer stage or histology, cigarette smoking or occupational exposure. A longer survival (not significant) was shown in seropositive LC but not in MM. p53 expression in tumor tissue was also evaluated in a subgroup of MM. In conclusion, the presence of detectable p53-Abs in serum was associated in a statistically significant proportion of cases with LC but only occasionally with MM. The longer survival among positive LC patients and the presence of two seropositive among patients with non-neoplastic respiratory diseases should be further investigated.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0169-5002
|
| pubmed:author |
pubmed-author:BettaPiergiacomoP,
pubmed-author:CafferataMaraM,
pubmed-author:FilibertiRosangelaR,
pubmed-author:IvaldiGiampaoloG,
pubmed-author:MarroniPaolaP,
pubmed-author:MereuCarloC,
pubmed-author:MontanaroFabioF,
pubmed-author:NeriMonicaM,
pubmed-author:PaganuzziMichelaM,
pubmed-author:PuntoniRiccardoR
|
| pubmed:copyrightInfo |
Copyright 2002 Elsevier Science Ireland Ltd.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
165-72
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12581569-Aged,
pubmed-meshheading:12581569-Antibodies, Neoplasm,
pubmed-meshheading:12581569-Autoantibodies,
pubmed-meshheading:12581569-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12581569-Carcinoma, Small Cell,
pubmed-meshheading:12581569-Carcinoma, Squamous Cell,
pubmed-meshheading:12581569-Case-Control Studies,
pubmed-meshheading:12581569-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:12581569-Female,
pubmed-meshheading:12581569-Humans,
pubmed-meshheading:12581569-Lung Diseases,
pubmed-meshheading:12581569-Lung Neoplasms,
pubmed-meshheading:12581569-Male,
pubmed-meshheading:12581569-Mesothelioma,
pubmed-meshheading:12581569-Middle Aged,
pubmed-meshheading:12581569-Neoplasm Staging,
pubmed-meshheading:12581569-Pleural Effusion, Malignant,
pubmed-meshheading:12581569-Pleural Neoplasms,
pubmed-meshheading:12581569-Prognosis,
pubmed-meshheading:12581569-Prospective Studies,
pubmed-meshheading:12581569-Risk Factors,
pubmed-meshheading:12581569-Survival Rate,
pubmed-meshheading:12581569-Tumor Markers, Biological,
pubmed-meshheading:12581569-Tumor Suppressor Protein p53
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.
|
| pubmed:affiliation |
Division of Environmental Epidemiology, National Cancer Research Institute, Largo Rosanna Benzi 10, I-16132 Genoa, Italy. monica.neri@istge.it
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|